<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="146305">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01913886</url>
  </required_header>
  <id_info>
    <org_study_id>MSC_Isquemica</org_study_id>
    <nct_id>NCT01913886</nct_id>
  </id_info>
  <brief_title>Mesenchymal Stem Cells to Treat Ischemic Cardiomyopathy</brief_title>
  <official_title>Autologous Grafting of Mesenchymal Stem Cells in Severe Refractory Ischemic Cardiomyopathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Danielle Malheiros</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Santa Casa de Misericórdia de Curitiba, Brazil</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Fundação Araucária, Brazil</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Pontifícia Universidade Católica do Paraná</source>
  <oversight_info>
    <authority>Brazil: National Committee of Ethics in Research</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the safety and efficacy of intracoronary injection of mesenchymal
      stem cells (MSCs) to repair heart function in patients with myocardial ischemia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Ischemic heart disease is a major public health problem in the industrialized and developing
      world. Current research is focusing on the development of cell-based therapies using stem
      cells to treat heart failure. Mesenchymal stem cells (MSCs) can differentiate into
      endothelial cells and participate in the development of new blood vessels in the heart
      damaged. Therefore, MSCs has shown promise for heart repair. The investigators study will
      evaluate the safety and efficacy of intracoronary injection of mesenchymal stem cells (MSCs)
      to repair heart function in patients with myocardial ischemia.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2010</start_date>
  <completion_date type="Anticipated">July 2014</completion_date>
  <primary_completion_date type="Actual">September 2013</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Change from baseline in left ventricular ejection fraction (LVEF) measured by echocardiogram.</measure>
    <time_frame>3 months</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in quality of life</measure>
    <time_frame>3 months, 6 months, 12 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Measures by specific questionnaire of quality of life: Minnesota Living with Heart Failure Questionnaire (MLHFQ)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in exercise capacity</measure>
    <time_frame>1 year</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in plasma inflammatory markers</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Ischemic Cardiomyopathy</condition>
  <arm_group>
    <arm_group_label>MSCs injection</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Injection of autologous bone marrow-derived mesenchymal cells</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>MSCs injection</intervention_name>
    <description>MSCs cells will be injected in two aliquots of 10 ml by catheterism</description>
    <arm_group_label>MSCs injection</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Chronic coronary artery disease

          -  NYHA (Heart failure) Class II-IV or Angina pectoris CCS Class III or IV or symptoms
             consistent with.

          -  Ejection fraction between 35% and 55%.

          -  Stable medical therapy for at least one month

          -  Patients clinically treated with coronary angioplasty with or without intraluminal
             stent.

          -  Patients with surgical revascularization and without the possibility of new invasive
             intervention.

        Exclusion Criteria:

          -  Human immunodeficiency virus (HIV1-2), HTLV-1 and 2.

          -  An active uncontrolled infection.

          -  Pregnancy.

          -  Mental disability.

          -  Terminal illnesses.

          -  Valvular heart disease, congenital heart disease or other causes of cardiomyopathy
             than ischemic.

          -  Life perspective by other diseases under 1 year.

          -  History of severe arrhythmias

          -  Renal dysfunction or against medication

          -  Inability to perform cardiac catheterization.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paulo Brofman, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Pontifícia Universidade Católica do Paraná</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Paulo Brofman, PhD</last_name>
    <phone>+55 41 3271 2219</phone>
    <email>paulo.brofman@pucpr.br</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Alexandra Senegaglia, PhD</last_name>
    <phone>+55 41 3271 2219</phone>
    <email>alexandra.senegaglia@pucpr.br</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Pontifícia Universidade Católica do Paraná</name>
      <address>
        <city>Curitiba</city>
        <state>Paraná</state>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carmen Rebelatto, PhD</last_name>
      <phone>+55 41 32712219</phone>
      <email>carmen.rebelatto@pucpr.br</email>
    </contact>
    <investigator>
      <last_name>Paulo Brofman, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 30, 2014</lastchanged_date>
  <firstreceived_date>July 30, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Pontifícia Universidade Católica do Paraná</investigator_affiliation>
    <investigator_full_name>Danielle Malheiros</investigator_full_name>
    <investigator_title>PhD</investigator_title>
  </responsible_party>
  <keyword>Cardiovascular Diseases</keyword>
  <keyword>Myocardial Ischemia</keyword>
  <keyword>Coronary Artery Disease</keyword>
  <keyword>Heart Diseases</keyword>
  <keyword>Coronary Disease</keyword>
  <keyword>Ventricular Dysfunction</keyword>
  <keyword>Arteriosclerosis</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Ischemia</mesh_term>
    <mesh_term>Cardiomyopathies</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
